INTRODUCTION {#s1}
============

The prognosis for pancreatic ductal adenocarcinoma (PDAC) remains dismal with 5-year survival rates of 6% and 85--90% of PDACs are found out to be inoperable at the time of diagnosis \[[@R1]\]. One of the major limitations to study tumor biology of PDACs was due to difficulties acquiring tissue specimens from most of unresectable PDACs. The majority of what is known about PDACs so far comes from the surgical specimens which only comprise 20% of the PDAC population. The remaining 80% of patients have locally advanced or metastatic disease in these patients little to no data is available because of access to tissues. Recently, endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) method has become a gold standard in the diagnosis of PDACs and became the most promising tool as a diagnostic modality \[[@R2]--[@R5]\]. However, the aspirated specimen obtained by this technique sometimes insufficient to make a definite cytopathological diagnosis \[[@R3], [@R6]--[@R9]\]. Therefore, it is very important to investigate the diagnostic modality with high accuracy and being capable of getting sufficient tissue for PDACs.

The *KRAS* gene is the locus for the *c-k-ras* proto oncogene located on the short arm of chromosome 12 (12q) and the majority of mutations have been found at *KRAS* codons 12 and 13. *KRAS* mutations are the most frequently acquired genetic alteration in PDAC, and detecting this mutation from pancreatic tissue has been helpful in the diagnosis of pancreatic cancer \[[@R5], [@R10]\]. Previous studies revealed that the combined modality of cytopathology and *KRAS* mutations detection could improve the sensitivity of the diagnosis of pancreatic cancer \[[@R5], [@R10], [@R11]\]. Although conventional PCR amplification followed by direct sequencing has been the gold standard for the detection of *KRAS* gene mutation to date, this technique has low sensitivity \[[@R12], [@R13]\]. It can detect only mutant sequences that contain more than 25% of total gene content \[[@R13], [@R14]\]. To overcome this drawback, several alternative modalities were devised. The peptide nucleic acid (PNA)-mediated PCR clamping technique is a modified PCR technology by using optimized PNA probes \[[@R12]\]. PNA is a synthetic DNA analog in which the phosphodiester backbone is replaced by a peptide-like repeat of the (2-aminoethyl)-glycine chain \[[@R15], [@R16]\]. The above mentioned structural characteristics lead to the thermal stability of PNA-DNA duplexes than the corresponding DNA-DNA duplexes \[[@R17]\]. The PNA has tight binding to the wild type DNA fragments and eventually resulted in no amplification for wild type DNA \[[@R17]\]. On the other hands, the PCR amplification is processed for multiplication In the case of mutated genes, such as SNPs, of the mutated DNA sequences \[[@R17]\]. This technique can detect *KRAS* gene mutation using a tiny amount of specimen obtained by EUS-FNA \[[@R18]--[@R20]\]. The combination of conventional cytopathological diagnosis and *KRAS* mutation analysis with modified PCR technology was investigated to improve the sensitivity of diagnosis for the PDAC \[[@R5]\].

RESULTS {#s2}
=======

Baseline characteristics {#s2_1}
------------------------

The total of 43 study patients underwent EUS-FNA and tissue specimen was acquired successfully (Table [1](#T1){ref-type="table"}). Of the 43 patients there were a total of 26 (60.5%) males and 17 (39.5%) females. The mean age in the group was 61.4±13.3 years, range 19-85 years. The locations of the lesions in pancreas were as follows; head and uncinate of the pancreas in 24 patients, body in 12 patients and tail in 7 patients. The average size of the mass in study patients was 33.0±12.3 mm. There was no significant difference in size among the pancreas mass according to the final diagnosis; PDAC (median 31.8 mm, 10 \~ 80), pancreas neuroendocrine tumor (PNETs; median 25.2 mm, range 16 to 40), and inflammatory mass due to pancreatitis (27.5 mm, range 20 to 30). EUS-FNA was performed with 22 gauge or 25 gauge needle and the average number of needle pass was 3.5 times (Table [1](#T1){ref-type="table"}). Among the 43 patients, final diagnoses were as follows; 23 PDACs and 20 non-PDACs: PNET, inflammatory mass with pancreatitis, metastatic GB cancer, solid pseudopapillary neoplasm (SPN), serous cystadenoma and metastatic renal cell carcinoma (RCC) (Table [2](#T2){ref-type="table"}).

###### Baseline characteristics (n=43)

  -------------------------------------- -----------
  Sex (male/female)                      26/17
  Age (y)                                61.4±13.3
  Location (head & uncinate/body/tail)   24/12/7
  Size (mm)                              33.0±12.3
  Needle (22G:25G)                       32:11
  Passing number (times)                 3.5 ±0.8
  -------------------------------------- -----------

###### Final diagnosis (n=43)

  ----------------------- ----
  PDACs\*                 23
  Non-pancreatic cancer   20
   Neuroendocrine tumor   5
   Pancreatitis           4
   Metastatic GB cancer   2
   SPN+                   2
   Serous cystadenoma     2
   Metastatic RCC         1
   Other benign disease   4
  ----------------------- ----

Cytopathologic diagnosis {#s2_2}
------------------------

This study was to investigate the diagnostic modality which would increase the accuracy and sensitivity in evaluating minimal specimens from EUS-FNA. In addition, EUS-FNA for pancreatic mass usually have not sufficient amount of tissue and therefore, to develop diagnostic technique which is capable of adding more information in diagnosis of PDAC would be very useful in clinical practice. There were 86 study samples and the final diagnosis were the followings; 46 PDACs and 40 non-PDACs such as 5 PNETs, 4 pancreatitis, 2 metastatic GB cancers, 2 SPNs, 2 serous cystadenomas, 1 metastatic RCC and 4 other benign diseases (Table [2](#T2){ref-type="table"}, Figure [1](#F1){ref-type="fig"}). Among the 46 PDAC samples, 29 samples were positive for adenocarcinoma cells in cytology samples. There were 17 samples with negative results from the cyotologic examination such as; atypical cells, inadequate samples due to low cellularity and without malignant cells. The sensitivity, specificity and overall accuracy for cytopathologic diagnosis of pancreatic cancer were 63%, 100%, and 80%, respectively (Table [3](#T3){ref-type="table"}).

###### (A) Cytopathological examinations

                  Pathology Y   Pathology N
  --------------- ------------- -------------
  PDAC Y (N=46)   29            17
  PDAC N (N=40)   0             40

###### (B) Combined cytopathological examinations and K-ras mutation analysis

           Pathology/K-ras Y   Pathology/K-ras N
  -------- ------------------- -------------------
  PDAC Y   40                  6
  PDAC N   0                   40

###### (C) Sensitivity, specificity and overall accuracy of the diagnosis of PDACs

                        Sensitivity (%)   Specificity (%)   Accuracy (%)
  --------------------- ----------------- ----------------- --------------
  Cytopathology         29/46 (63%)       40/40 (100%)      68/86 (80%)
  Combination of both   40/46 (87%)       40/40 (100%)      80/86 (93%)

![Final diagnosis, cytopathology and KRAS mutation](oncotarget-08-3519-g001){#F1}

Detection of *KRAS* mutations {#s2_3}
-----------------------------

Among the 46 PDAC samples, 29 samples were positive for adenocarcinoma cells in cytology samples. There were 17 samples with negative results from the cyotologic examination such as; atypical cells, inadequate samples due to low cellularity and without malignant cells. K-ras mutation analysis from the washing fluid of cytology negative samples was as follows; 11 out of 17 samples were positive for K-ras mutation analysis. Also, there were also 40 non--PDAC samples and 39 samples were found no K-ras mutation except for one sample whose histologic diagnosis from EUS-FNA was PNET (Figure [1](#F1){ref-type="fig"}).

Combination of cytopathology and *KRAS* mutation analysis {#s2_4}
---------------------------------------------------------

Tissue specimens from the EUS-guided FNA & FNB were acquired and after the procedure, the needles and apparatus would be disposed. However, we have used washing fluid passing through the needles and analyzed K-ras mutation status. Using washing fluid samples was our original idea in this study and it usually wouldn\'t be existed in routine clinical practice. There were 86 study samples and the final diagnoses were the followings; 46 PDACs and 40 non-PDACs: 5 PNETs, 4 pancreatitis, 2 metastatic GB cancers, 2 SPNs, 2 serous cystadenomas, 1 metastatic RCC and 4 other benign diseases. Among the 46 PDAC samples, the 29 samples were positive and rest of the 17 samples were negative or not definitive for ductal adenocarcinoma cells from the cytopathologic examination. However, *KRAS* mutant gene was detected in 11 out of 17 samples and it contributed to the diagnosis of PDACs. Also, there were 39 out of 40 non--PDAC samples found no K-ras mutation except for one sample whose histologic diagnosis from EUS-FNA was pancreas neuroendocrine tumor. In Table [3](#T3){ref-type="table"}, each cytopatholgical examination and combined result was as follows. In cytopathological examinations, sensitivity, specificity and accuracy were 63%, 100% and 80% (Figure [2](#F2){ref-type="fig"}). When it is combined with K-ras mutation analysis from washing fluid during EUS-FNA & FNB, they became 87%, 100% and 93% respectively (Table [3](#T3){ref-type="table"}, Figure [2](#F2){ref-type="fig"}). As we have described in the above paragraphs, combination of cytopathology and KRAS mutation analysis was very helpful as diagnostic modality for PDACs. There was a 45-year old woman presented with epigastric and back pain among study patients. Abdominal CT scanning showed a solid mass like lesion with cystic changes in the head of pancreas accompanied by bile duct dilatations. FNA was performed and two separate aspirated samples were obtained. Cytopathological diagnosis for the first EUS-FNA specimen was "consistent with adenocarcinoma" and "a few inflammatory cells present" for the second one. In spite of the inconsistency of cytopathological examinations, *KRAS* mutations were detected in both of samples.

![Sensitivity, specificity and accuracy for the diagnosis of PDAC](oncotarget-08-3519-g002){#F2}

Complications {#s2_5}
-------------

There were no complications associated with EUS-FNA in study patients.

DISCUSSION {#s3}
==========

PDAC has one of the lowest survival rate among the malignant solid tumors and it is approximately 5% for all stages combined \[[@R1]\]. Majority of PDACs usually are found in locally advanced or metastatic disease at the time of diagnosis. Early detection of PDAC and complete surgical resection is the only chance to improve 5-year survival rate up to 20%. Recently EUS-FNA has been established as a gold standard for the diagnosis of PDAC \[[@R2]--[@R5]\]. EUS-FNA is more safe and effective than percutaneous ultrasonography- or CT-guided FNA, because it can avoid vessels by using color doppler and make shorter track to the intrapancreatic masses. However, EUS-FNA technique still implies some drawbacks like the relatively low negative predictive value (NPV) for the diagnosis of PDACs \[[@R21], [@R22]\]. It is noteworthy to point out that a negative result of cytopathology cannot rule out pancreatic cancer, because the accuracy of cytopathologic diagnosis from FNA specimens depends upon accurate sampling \[[@R3]\]. Moreover, even if we got the specimen from the accurate target, the amount of aspirated material could be too small to make a definite cytopathologic diagnosis and additional punctures could be needed. To overcome these drawbacks, a number of different diagnostic modalities have been investigated.

*KRAS* mutation is one of the most frequent and important genetic alterations in PDAC, and the combined modality of cytopathology and *KRAS* mutation analysis could improve the sensitivity in diagnosing PDACs \[[@R5], [@R10], [@R11]\]. Takahashi et al. analyzed *KRAS* mutation in EUS-FNA specimens by direct sequencing to facilitate a differential diagnosis between PDAC and focal pancreatitis \[[@R10]\]. They reported the sensitivity according the following diagnostic modalities; cytopathology, *KRAS* mutation analysis and the combination of cytopathology and *KRAS* mutation analysis were 84%, 74% and 94%, respectively \[[@R23]\]. As above study showed, the sensitivity for the diagnosis of PDAC improved markedly, from 82% to 94%, in cases of PDAC when the presence of the *KRAS* mutation was taken into consideration \[[@R10]\]. But more punctures of EUS-FNA should be performed to carry out *KRAS* mutation analysis \[[@R10]\]. Tada et al. performed the quantitative analysis of *KRAS* mutation by using washing fluid from FNA needle catheter \[[@R5]\]. In their study, the sensitivity of cytopathology, *KRAS* mutation analysis and the combination of cytopathology and *KRAS* mutation analysis was 62%, 77% and 81%, respectively \[[@R23]\]. They also reported that no *KRAS* mutations had been observed in non-cancer cases. *KRAS* mutation analysis supplemented conventional cytopathology of EUS-FNA, up by 19%. But the detection rate of *KRAS* mutation by quantitative analysis technique is slightly lower compare to other studies used resected pancreatic specimens \[[@R5], [@R10]\]. The conventional PCR amplification technique followed by direct sequencing can detect only mutant sequences that contain \> 25% of total gene content \[[@R14]\].

To improve the sensitivity of pancreatic cancer diagnosis and to avoid additional punctures, we have applied the *KRAS* mutation analysis technique with modified PCR technology using the washing fluid after EUS-FNA. The PNA-mediated PCR clamping technique is a modified PCR technology by using optimized PNA probes \[[@R12]\]. PNA is a synthetic DNA analog, phosphodiester backbone is replaced by a peptide-like repeat of the (2-aminoethyl)-glycine chain \[[@R15], [@R16]\]. The structural characteristics lead to the thermal stability of PNA-DNA duplexes over the corresponding DNA-DNA duplexes \[[@R17]\]. The tight binding of PNA to the wild type DNA fragments results in no amplification of the wild type DNA fragments. However, in the case of mutated genes, especially with SNPs, the PCR amplification is processed for multiplication of the mutated DNA sequences. This technique can detect *KRAS* gene mutation using a tiny amount of specimen obtained by EUS-FNA \[[@R18]--[@R20]\].

Jeoung et al. evaluate the efficacy of PNA-clamp real-time PCR technique compared to the conventional direct sequencing \[[@R13]\]. They reported that PNA-based real-time PCR clamping technique was more sensitive than direct sequencing for detecting *KRAS* mutation \[[@R13], [@R24]\]. The PNA-based real-time PCR clamping detected 1% of mutant genes in 1 ng DNA. Kobunai et al. reported a sensitivity of 0.4% in 2 ng DNA using cell lines and the PNA-clamp real-time PCR SYBR assay \[[@R25]\].

In this study, we performed the PNA mediated PCR clamping technique using washing fluid after EUS-FNA and the combination of cytopathology and *KRAS* mutation analysis showed a sensitivity of 87.0%, up by 26.1% compared with cytopathologic examination alone. It is noteworthy that this method detects *KRAS* mutation without additional invasive try or efforts, because it can be performed only with the washing fluid of EUS-FNA needle after puncture.

Definitely, *KRAS* mutation analysis could be a supplement to the conventional cytopathological diagnosis, when only "atypical cells or suspicious of malignancy" was reported in spite of clinically strong suspicion of malignancy or when aspirated specimens were too small to make a definite diagnosis. Cytopathologic examination is a gold standard diagnostic modality and we had the sensitivity and accuracy of 63% and 80% respectively. Compared to the previous studies which reported 62\~94% of sensitivity, our result show only 63% of low sensitivity \[[@R5], [@R10], [@R26]\]. We have included the 4 samples with the inadequate specimens for cytopathological examination, but *KRAS* mutation was detected for all those samples. Therefore, For example, one case was 54-year old man who presented with epigastric discomfort. Abdomen CT scanning showed about 5.3 cm sized mass lesion in the pancreatic tail. Four times to and fro motions were done and four separate samples were obtained. Cytopathological examinations for the first two specimens were reported as 'a few atypical cell clusters' and 'suspicious for malignancy', but 'Scanty cellular smear' for the last two samples. In spite of the uncertainty of cytopathological diagnosis, *KRAS* mutation was detected. The final diagnosis was PDAC after the surgical confirmation.

On the other hands, there were 39 out of 40 non--PDAC samples without K-ras mutations except for one sample whose histologic diagnosis was PNETs. There is a possibility that K-ras mutation was picked up from the adjacent PanIN lesions. However, this study was performed by endoscopic experts who had performed EUS-FNA more than 2,000 cases at the time of study enrollment and it is very hard to miss the target lesions. Moreover, K-ras mutation in PNET has been reported in several studies. Jiao et al first reported genomic landscape of pancreas neuroendocrine tumors \[[@R27]\]. They had 10 PNETs for the discovery set and found 8 to 23 mutations per tumor, however, the frequently mutated genes in PDACs such as TP53, KRAS, CDKN2A and SMAD4 were not found in their PNET samples. Interestingly, Jiao et al studied 43 PNETs in Chinese population and found out the frequently mutated genes as follows; DAXX/ATRX, KRAS, MEN1, mTOR pathway genes (PTEN, TSC2), SMAD4/DPC, TP53 and VHL were mutated in 54%, 11%, 54%, 3%, 14% and 41% respectively \[[@R27]\]. The mutation rates of above mentioned genes in Chinese PNET patients are different from those in Caucasians that there were a higher number of mutated genes \[[@R27]\]. Furthermore, the DAXX/ATRX and KRAS gene mutations are correlated with a poor prognosis of patients with PNETs \[[@R27]\]. We don\'t know yet whether those different results are due to the ethnic differences or picking up adjacent PanIn lesion either. False positive for K-ras mutation issue needs to be further investigated.

Most of PDACs are unresectable and there are often not sufficient tissue samples which can be used for diagnosis and not to mention research material of PDAC biology. We have tried to increase the diagnostic accuracy without using additional tissue specimens. Here, we report both combined modalities cytopathological examination and KRAS mutation analysis with PNA mediated PCR clamping technique (PNAClamp™) from EUS-FNA have successfully demonstrated its usefulness as diagnostic modality for PDACs. Moreover, it can be performed without additional efforts since it uses only washing fluid after EUS-FNA procedure. Furthermore, KRAS mutation was detected 11 out of 17 PDAC samples whose cytopathology results were inconclusive. Therefore, *KRAS* mutation analysis with PNAClamp™ technique using washing fluid from EUS-FNA along with cytopathological examination may not only improve the diagnostic accuracy of PDACs, but also establish the platform of genetic analysis which would be helpful as diagnostic modality for PDACs.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

A total of 43 consecutive patients were prospectively enrolled in this study and underwent EUS-FNA & FNB procedures at Samsung Medical Center, the tertiary teaching hospital. The value of *KRAS* mutational analysis from the washing fluid during EUS-FNA samples was evaluated whether it can be helpful along with the conventional cytopathology. The inclusion criteria was as follows; the patients who were found to have pancreatic mass on CT scan or MRI and those scheduled to undergo EUS-FNA for further evaluation. The patients with pancreatic mass and definite evidence of metastasis were excluded in this study. Informed consent for EUS-FNA was obtained from all patients, and this work was performed in accordance with the humane and ethical principles of research set forth in the Helsinki guidelines.

EUS-FNA technique {#s4_2}
-----------------

Patients received pharyngeal local anesthesia and were sedated with injections of 2 to 12 mg (average 4.8 mg) of midazolam. Standard EUS was first performed using a radial scanning echoendoscope (JF UM20; Olympus, Tokyo, Japan) and a 22-gauge or 25-gauge needle (NA-10J-1 or NA-11J-KB; Olympus, Tokyo, Japan) to identify and evaluate the lesions. EUS-guided FNA was then performed using a curved linear array echoendoscope (FG-36 UA; Pentax/Hitachi, Tokyo, Japan) with a GIP/Medi-Globe 22-gauge, 10-cm needle (GIP Medizin Technik, Grassau, Germany). After scanning the pancreatic masses with pulse and color Doppler methods to evaluate the lesion and presence of adjacent vessels, a catheter was inserted into the biopsy channel and the needle tip was advanced incrementally under real-time endoscopic guidance into the lesion. The EUS-FNAs were either transgastric or transduodenal, depending on the site of the lesion. The stylet was removed and suction was applied through a 20-ml syringe as the needle moved back and forth two to six times (average 3.5 times) within the lesion. The needle was then retracted into the catheter and the entire catheter was removed. The aspirated materials were placed onto glass slides by releasing the syringe and direct smears were prepared. FNA samples were stained using the rapid Hematoxylin and Eosin (H&E) staining technique. Then the needle catheter was flushed with 2 ml of saline and residual materials were collected for DNA extraction. Those collected samples were frozen right after EUS-guided FNA and the storage kept the specimens in −80°C.

Cytopathological diagnosis {#s4_3}
--------------------------

Definitive cytopathological diagnosis was stated by a single pathologist, blinded to the result of EUS, after staining. The pathologist was provided a clinical history as well as the site and size of the mass lesion. For classification, the cytology specimens were interpreted as benign, atypical or suspicious of malignancy, malignant, or inadequate specimens if representative material was not present. The only judgment of "malignant" was accepted as a definite diagnosis of malignancy.

Analysis of *KRAS* gene mutation {#s4_4}
--------------------------------

DNA was extracted from aspirated specimens by high pure PCR template preparation kit (Roche, Mannheim, Germany), according to the manufacturer\'s instructions, and the amount of DNA was measured by Nano Drop Product (Thermo Scientific, Wilmington, DE). The DNAs were diluted to a concentration representing 50 ng/μL for the test. *KRAS* gene was analyzed by PNAClamp™ KRAS Mutation Detection Kit (Panagene, Daejeon, Korea). This assay is based on PNA-mediated real-time PCR clamping technology. PNA is a synthetic DNA analog in which the phosphodiester backbone is replaced by a peptide-like repeat formed by (2-aminoethyl)-glycine units (Figure [3](#F3){ref-type="fig"}). Since PNA contains no charged phosphate groups, the binding between PNA/DNA is stronger than between DNA/DNA due to the lack of electrostatic repulsion (Figure [3](#F3){ref-type="fig"}). Briefly, PCR amplification was performed in a total volume of 20 μL that contained 50 ng of DNA, 13 μL of real-time SYBR Green PCR master mix and each of the primers and PNA probes for codons 12/13, respectively. The PCR control lacked a PNA probe. The PCR cycling conditions were at 94°C for 5 minutes followed by 40 cycles of 94°C for 30 sec, 70°C for 20 sec, 63°C for 30 sec, and 72°C for 30 sec and a final extension of 72°C for 5 minutes. The PNA probe was designed to hybridize completely to the wild-type *KRAS* allele to suppress amplification of wild-type target, thereby enhancing preferential amplification of mutant sequences by competitively inhibiting DNA primer binding to wild-type DNA. PCR efficiency was determined by measuring the threshold cycle (Ct) value. Obtain Ct values for the control and mutation assays by observing the SYBRGreen amplification plots. Delta-Ct values were calculated as the Ct value of the PCR with the PNA control minus the Ct value of the PCR of the samples. The higher delta-Ct value means that the mutant was efficiently amplified. The cutoff value of 2.0 was used for determining the presence of mutant DNA. Theses molecular analyses were provided by Panagene (Daejeon, Korea) in exchange for studying a large number of clinical samples for the diagnosis of pancreatic cancer. Permission to disclose molecular results without notification of the patient\'s clinical information was obtained in advance from the company.

![Analysis of KRAS gene Mutation: PNAClamp KRAS Mutation Detection Kit](oncotarget-08-3519-g003){#F3}

Statistical analysis {#s4_5}
--------------------

Statistical differences between the 2-paired results obtained from cytopathologic diagnosis and the combination of conventional cytopathology and *KRAS* mutation analysis were analyzed by the McNemar test. The t-test was used for analysis of tumor size. SPSS Statistical Analysis Software (v19; SPSS, Chicago, IL, USA) was used for statistical analysis. A *p*-value of \<0.05 was considered statistically significant.

Abbreviations {#s4_6}
-------------

PDAC; pancreatic ductal adenocarcinoma, EUS-FNA; endoscopic ultrasound fine needle aspiration, EUS-FNB; endoscopic ultrasound fine needle biopsy, PNET; pancreas neuroendocrine tumor, SPN; solid pseudopapillary neoplasm, RCC; renal cell carcinoma.
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